Less is more: low expression of MT1-MMP is optimal to promote migration and tumourigenesis of breast cancer cells by unknown
RESEARCH Open Access
Less is more: low expression of MT1-MMP
is optimal to promote migration and
tumourigenesis of breast cancer cells
Mario A. Cepeda1*, Jacob J. H. Pelling1, Caitlin L. Evered1, Karla C. Williams3, Zoey Freedman1, Ioana Stan1,
Jessica A. Willson1, Hon S. Leong2,3 and Sashko Damjanovski1,4*
Abstract
Background: Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) is a multifunctional protease implicated in
metastatic progression ostensibly due to its ability to degrade extracellular matrix (ECM) components and allow
migration of cells through the basement membrane. Despite in vitro studies demonstrating this principle, this
knowledge has not translated into the use of MMP inhibitors (MMPi) as effective cancer therapeutics, or been
corroborated by evidence of in vivo ECM degradation mediated by MT1-MMP, suggesting that our understanding
of the role of MT1-MMP in cancer progression is incomplete.
Methods: MCF-7 and MDA-MB 231 breast cancer cell lines were created that stably overexpress different levels
of MT1-MMP. Using 2D culture, we analyzed proMMP-2 activation (gelatin zymography), ECM degradation (fluorescent
gelatin), ERK signaling (immunoblot), cell migration (transwell/scratch closure/time-lapse imaging), and viability
(colorimetric substrate) to assess how different MT1-MMP levels affect these cellular parameters. We also utilized
Matrigel 3D cell culture and avian embryos to examine how different levels of MT1-MMP expression affect
morphological changes in 3D culture, and tumourigenecity and extravasation efficiency in vivo.
Results: In 2D culture, breast cancer cells expressing high levels of MT1-MMP were capable of widespread
ECM degradation and TIMP-2-mediated proMMP-2 activation, but were not the most migratory. Instead, cells
expressing low levels of MT1-MMP were the most migratory, and demonstrated increased viability and ERK
activation. In 3D culture, MCF-7 breast cancer cells expressing low levels of MT1-MMP demonstrated an invasive
protrusive phenotype, whereas cells expressing high levels of MT1-MMP demonstrated loss of colony structure and cell
fragment release. Similarly, in vivo analysis demonstrated increased tumourigenecity and metastatic capability for cells
expressing low levels of MT1-MMP, whereas cells expressing high levels were devoid of these qualities despite the
production of functional MT1-MMP protein.
Conclusions: This study demonstrates that excessive ECM degradation mediated by high levels of MT1-MMP is
not associated with cell migration and tumourigenesis, while low levels of MT1-MMP promote invasion and
vascularization in vivo.
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Background
During metastatic progression, cancer cells detach
from the primary tumour into the surrounding extra-
cellular matrix (ECM). A subpopulation of these cells
will intravasate into the blood stream or lymphatic
vessels, entering the circulation [1]. Due to their size,
these disseminated cancer cells will eventually ex-
travasate via transendothelial migration, and a small
proportion will go onto proliferate to form secondary
colonies [2–4]. Matrix Metalloproteinases (MMPs)
have been implicated as the central mediators of
ECM remodeling throughout the metastatic cascade,
particularly Membrane Type-1 MMP (MT1-MMP),
MMP-2, and −9 [5–7]. Collectively, these MMPs play
a key role in the degradation of the major structural
components of the basement membrane (BM), which
separates the primary tumour from the endothelium
and is the first main structural barrier to metastasis
[8, 9]. It was long thought that the role of MMPs
was to mediate movement of cancer cells through the
BM via their ability to degrade ECM components;
however, MMPs are now known to be more pleio-
tropic than previously thought [10], participating in a
multitude of cell processes during cancer progression
[11, 12], and perhaps also acting as transcription
factors [13–15],
MT1-MMP (MMP-14) is multifunctional MMP that af-
fects cell behavior via proteolytic and non-proteolytic
mechanisms [16, 17]. As a result of its proteolytic activity,
MT1-MMP can cleave ECM and non-ECM substrates
[5, 18], and participates in activation of the pro-forms
of MMP-2 and MMP-9 [19, 20]. MT1-MMP also signals
through the ERK and AKT pathways [21, 22] and medi-
ates HIF-1α stabilization [23] via non-proteolytic mecha-
nisms. Moreover, it has been shown that MT1-MMP
overexpression also increases the migratory ability of
breast cancer cells independent of its proteolytic activity
[24, 25]. The mechanism underlying this increase in
migratory potential remains poorly understood, with evi-
dence suggesting that it involves ERK activation and cleav-
age of the cell adhesion molecule CD44 [26, 27]. However,
reported data reveal contradictions regarding the require-
ment for TIMP-2 in increasing migratory potential, as
some report the necessity for TIMP-2 to increase migra-
tion of cancer cells overexpressing MT1-MMP [24, 25],
whereas others did not using similar cell models [26–28].
Other experimental inconsistencies regarding the source
of MMPs, whether they are predominately stromal or
cancer cell derived [29], and their role in mediating cancer
cell growth and invasion in vivo are also under intense
debate [7, 9, 30, 31].
To address this, we overexpressed MT1-MMP in
MCF-7 breast cancer cells, which represent early stage
breast cancer [32] and are naturally MT1-MMP deficient
[33, 34], and for these reasons are commonly used by
others to understand the effects of MT1-MMP overex-
pression [21, 24, 25, 27, 28]. We determined that high
levels of MT1-MMP expression did not correlate with
migratory potential, and rather that low levels of MT1-
MMP are optimal to enhance migration. Similarly, we
showed that overexpression of MT1-MMP in MDA-
MB-231 cells, which are naturally invasive and express
endogenous MT1-MMP [32, 34, 35], decreased their
migratory potential and viability rather than enhanced it.
These observations are consistent across platforms, both
ex vivo with 3D cell culture [36], and with in vivo
tumourigenesis and cancer cell extravasation assays [37],
which all demonstrate that low MT1-MMP expression is
optimal to induce a protrusive phenotype, increased in-
vasiveness and metastatic capability in vivo. Additionally,
we analyzed the level of MT1-MMP protein in human
21 T breast cancer cell lines, which represent a progres-
sion from atypical ductal hyperplasia (ADH) to invasive
mammary carcinoma (IMC), to show that the metastatic
cell line produces little MT1-MMP protein, consistent
with our conclusions using MCF-7 and MDA-MB 231
breast cancer cells. This “low MT1-MMP” migratory
phenotype is accompanied by concomitant levels of
TIMP-2, thus reconciling many conflicting studies on
proteolytic factors in primary human tumours.
Methods
Cell culture
MCF-7, MDA-MB 231 and HS578t human breast cancer
cell lines were obtained from the American Type Cul-
ture Collection (Manassas, VA). Cells were maintained
in DMEM/F-12 media (Thermo Fisher) supplemented
with 10 % FBS, 100 IU/ml penicillin, 100 μg/ml strepto-
mycin, and incubated at 37 °C and 5 % CO2.
cDNA clones and reagents
Human MT1-MMP (sc116990), TIMP-2 (sc118083) and
MMP-2 (sc321560) cDNA clones were purchased from
Origene and subcloned into the vector pcDNA 3.3
(Thermo Fisher). The generation of the ALA + TIMP-2
cDNA construct in pcDNA 3.3 is described in Walsh
et al. [38]. The following reagents were used: Recombin-
ant human TIMP-2 and 4-aminophenylmercuric acetate
(APMA) (Sigma-Aldrich), BB-94 (Batimastat), U-0126,
and AKT inhibitor IV (Santa Cruz), and Furin inhibitor II
(Millipore).
Antibodies
For immunoblot analysis, the following primary antibodies
were used: MT1-MMP (1:1000, AB6004, Millipore); MT1-
MMP (1:1000, AB51074, Abcam); Phospho-ERK1/2
(1:2000, D13.14.4E), ERK1/2 (1:2000, 137 F5) (Cell Signal-
ing Technology); TIMP-2 (1:1000, 3A4), β-Actin (1:1000,
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C4), and phospho-histone-3 (PH3) (1:5000, C1513)
(Santa Cruz). Goat anti-mouse IgG (H + L) (Bio-Rad)
and goat anti-rabbit IgG (H + L) (Thermo Fisher) HRP
conjugates were used as secondary antibodies (1:10000).
For immunofluorescence analysis we used MT1-MMP
antibody AB6004 (1:200), and anti-rabbit-IgG-Alexa488 or
Alexa594 (Thermo Fisher) as secondary antibodies (1:400).
Transfection and generation of stable cell lines
MCF-7 and MDA-MB 231 cells were seeded at a density
of 5×105 cells/ml and incubated for 24 h. Following
incubation, cells were transfected with Lipofectamine
2000 (Thermo Fisher) according to the manufacturer’s
instructions. For transient transfection experiments, cells
were incubated for 24 h after transfection and then uti-
lized for experiments.
Stable cell lines were generated by transfection of cells
with the respective cDNAs in the vector pcDNA 3.3,
which contains a neomycin mammalian selection marker.
Following transfection, cells were split 1:1000 and incu-
bated in media containing 1 mg/ml G-418 (VWR). Indi-
vidual colonies were selected after four weeks of
incubation in selection media and expanded to assay for
the levels of MT1-MMP by qPCR and immunoblotting.
Stable cells lines expressing an shRNA sequence targeting
MT1-MMP in the vector pRS (TR311445, Origene) were
generated in the same manner expect using puromycin
(2 μg/ml) as the selection antibiotic.
For zsGreen infection, cells were seeded at ~ 40 % density
in a 6-well cell culture dish in 3 ml of media with a final
concentration of 8 μg/ml polybrene and infected with
250 μL of virus. For virus production, the pLVX-ZsGreen1-
N1 lentiviral plasmid was used. Twenty-four hours post-
infection, the media containing virus was removed and
replaced with puromycin selection media (2 μg/ml) for
three days of incubation to select for infected cells.
Generation of MMP-2, TIMP-2 and ALA + TIMP-2
conditioned media (CM)
Conditioned media (CM) containing high levels of
MMP-2, TIMP-2, and ALA + TIMP-2 protein was cre-
ated by transfecting MCF-7 cells with cDNA constructs
coding for the respective proteins. Following a 24-h in-
cubation post-transfection, transfected cells were washed
with phosphate buffered saline (PBS) and incubated in
DMEM/F12 media without FBS for 24 h. The serum-
free CM was then collected, aliquoted and stored for
later use. Conditioned media from mock-transfected
cells was used as a control.
Quantitative real-time PCR
RNA was collected from cells using the RNeasy Kit
(Qiagen) and cDNA was synthesized from 1 μg of RNA
using qScript cDNA supermix (Quanta). MT1-MMP
mRNA levels were assayed by qPCR using PerfeCta
SYBR Green Supermix (Quanta) and a CXF connect real
time system with CFX manager software (Bio-Rad).
mRNA levels were quantified by the ΔΔCT method and
are displayed as fold change relative to parental MCF-7
cells. The level of GAPDH mRNA was used as the in-
ternal control. Primers are as follows: MT1-MMP; F:
gcagaagttttacggcttgca, R: tcgaacattggccttgatctc, GAPDH;
F: acccactcctccacctttga, R: ctgttgctgtagccaaattcgt [33].
Immunoblotting
Post-incubation cells were washed 3× with PBS (pH= 7.2)
and disrupted using lysis buffer (150 mM NaCl, 1 % NP-40,
0.5 % NaDC, 0.1 % SDS, 50 mM Tris pH 8.0) supple-
mented with protease/phosphate inhibitor (Thermo Scien-
tific). Cell lysates were homogenized by sonication and
15 μg aliquots were analyzed by immunoblotting with
MT1-MMP, TIMP-2, pH-3, β-actin, pERK1/2 or ERK1/2
primary antibodies, followed by incubation with the appro-
priate secondary HRP-conjugated antibody and detection
using SuperSignal West Pico chemiluminescent substrate
(Thermo Fisher). Protein lysate from human 21 T cell lines
were acquired as previously described [39].
Gelatin zymography and reverse zymography
Gelatin zymography and reverse zymography was done
using samples of serum-free media (15 μl) as described
previously [40]. To assess the proMMP-2 activation abil-
ity of MCF-7 cells, which endogenously express very low
levels of MMP-2 [34], proMMP-2 CM was added to cells
at a dilution of 30 μl proMMP-2 CM/mL SF media. For
reverse zymography, serum-free media conditioned for
24 h by HS578t cells was used as the source of active
MMP-2 within the gel, as these cells naturally express
high levels of MMP-2 [33].
Immunofluorescence
Samples for fluorescent gelatin degradation and 3D cul-
ture experiments were fixed and prepared for immuno-
fluorescence according to their respective protocols (see
below). MT1-MMP primary antibody (AB6004) was de-
tected using anti-rabbit IgG Alexa594 or Alexa488 for
Oregon green-488 gelatin degradation or 3D culture ex-
periments respectively. F-actin was stained with Alexa633
phalloidin (1:100, Thermo Fisher) and nuclei with 4′,6-
diamidino-2-phenylindole (1 μg/ml, BioShop Canada).
Samples were imaged using a Nikon A1R+ confocal
microscope (1.2 au) with a 20× dry or 60× oil-immersion
lens and presented using NIS Elements software.
Transwell assays
The migratory potential of cells was measured using 24-
well 8 μm pour transwell inserts (Corning Costar). Cells
(2×104) were seeded on the upper chamber of the
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transwell in serum-free media and allowed to migrate
towards the bottom chamber which was placed in
DMEM/F-12 media supplemented with 10 % FBS. Mi-
gration assays were done with uncoated transwell in-
serts, whereas invasion assays were done with inserts
coated with 20 % Matrigel. Cells that migrated to the
lower chamber of the transwell insert were quantified as
described previously [41]. Migrated cells were normalized
to MCF-7/MDA-MB 231 parental cells in control condi-
tions and are presented as a mean percentage ± SEM.
Scratch closure migration assay
Cells were seeded at a density of 1×106 cells in a 35 mm
cell culture dish and allowed to form a monolayer for
24 h. Following incubation, media was removed and a
scratch was made down the middle of the cell culture dish
with a 100 μl pipette tip. Cells were washed 3× with PBS
(pH 7.2) to remove cell debris and then incubated with
fresh media. After 2 h, 10 images were captured down the
length of the scratch that represent the ‘initial’ size of the
scratch for that sample. Every 24 h for 3 days, the same
area of the scratch was imaged to examine how cells mi-
grated to close the scratch. Scratch closure was quantified
using ImageJ 2.0.0 software by measuring the width of the
scratch each day and normalizing it to the initial size of
the scratch. Scratch closure is presented as a mean per-
centage of the initial scratch size ± SEM.
Celltiter96® proliferation assay
Cells were seeded in triplicate (5000 cells/well) onto a 96-
well cell culture dish in media supplemented with 10 %
FBS or serum-free media. Immediately after seeding, 20 ul
of Celltiter96® AQueous One Solution (Promega) was
added in triplicate to each sample to obtain an initial read-
ing and ensure that the different cell lines were seeded
equally. The OD at 490 nm was measured using a Bio-Rad
model 3550-UV microplate reader after incubating the
cells with the substrate for 2 h. The substrate was added at
the indicated day intervals and measured in the same way
as the initial measurement to create a growth curve over
that span, or to compare the effect of chemical inhibitors
on cell viability during prolonged serum-free incubation.
Fluorescent gelatin degradation assay
Coverslips were coated with either Oregon Green-488
gelatin (for IF analysis) or gelatin labeled using an
Alexa594 protein labeling kit (for live imaging analysis)
(Thermo Fisher) and used to analyze ECM degradation
as per Martin et al. [42]. Immunofluorescence conditions
are as described above.
Three-dimensional (3D) cell culture
Cells (2.5×104) were embedded in Matrigel (Corning
Costar) and processed for immunofluorescence as per
Cvetkovic et al. [43]. To quantify colony morphologies
observed in 3D culture, five random 50 μm Z-stacks
(2 μm step size) were acquired using DIC microscopy at
10× magnification every day for 5 days post-embedding.
For each individual Z-stack, invasive features (dissemina-
tions and protrusions, see text) were blindly counted
and normalized to the number of circular colonies per
field of view. Immunofluorescence procedure was done
as described above using 3 % BSA/PBS as the blocking
buffer. Single cells (marked by DAPI), F-actin dissemina-
tions, F-actin protrusions and zsGreen protrusions were
blindly counted from 20× 3D volumes and normalized
to the number of circular colonies per field of view.
Live-imaging and timelapse movies
Cells were embedded in Matrigel or seeded on Alexa594
gelatin coverslips as described above and placed in a live
imaging chamber mounted on the stage of a Leica
DM16000 B fluorescent microscope. To analyze the rela-
tionship between ECM degradation and migration, cells
stably expressing zsGreen were incubated on Alexa594
gelatin coverslips and imaged at the same stage position at
10× magnification every 10 min for 20 h. These images
were then compiled into timelapse movies using ImageJ.
The zsGreen channel timelapse movies were used to
quantify the migration of individual cells in an automated
manner using the ADAPT plugin for ImageJ [44]. The
ADAPT plugin (v1.146) was used with default conditions
and the trajectory visualization output was used to group
cells according to the distance migrated. The Alexa594
gelatin channel was used to manually quantify the per-
centage of cells that had degraded the underlying gelatin
at different time points. To visualize the dynamics of cells
in 3D culture, cells were embedded in Matrigel and z-
stacks (100 μm, 5 μm step size) were acquired at 20×
magnification every 30 min for 72 h. Focal panels showing
colony features with the greatest clarity were isolated and
compiled into timelapse movies using ImageJ.
Avian embryo CAM implantation and extravasation
efficiency assay
For implantation experiments, the superficial layer of
the CAM of day 9 chicken embryos was removed to ex-
pose the underlying capillaries [45]. MDA-MB 231,
MCF-7 or MCF-7 MT1-MMP cell lines stably expressing
zsGreen were then resuspended in Matrigel and pipetted
onto the exposed capillaries (5×105 cells in 10 μl Matri-
gel/embryo). Eight days post-implantation the resulting
tumour was imaged using a fluorescent stereoscope to
examine vascularization of the tumour shown by the
presence of non-fluorescent CAM vessels within the
zsGreen tumour.
MCF-7 and MCF-7 MT1-MMP cell lines stably ex-
pressing zsGreen were used for intravenous injection
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into the CAM vasculature of day 14 chicken embryos
and extravasation efficiency was quantified 24 h post-
injection as per Kim et al. [37].
Densitometry analysis
Quantitative analysis of immunoblots was done using
QuantityOne software (Bio-Rad). Band intensity was ob-
tained for the pERK and total ERK signal of each sample
from three independent experiments. ERK activation is
presented as a ratio between the pERK and the total
ERK band intensity within each sample normalized to
MCF-7 cells under control conditions.
Statistics
Statistical analysis and graphing was performed using
GraphPad Prism version 6.0 (GraphPad software, La
Jolla, CA, USA). Data is presented as mean ± SEM. One-
way ANOVA followed by Tukey’s post-hoc test was used
unless otherwise indicated in the figure legend. Signifi-
cant differences denoted by asterisks are shown versus
MCF-7 or MDA-MB 231 parental cells in control condi-
tions unless otherwise shown in figure. Different levels
of statistical significance are denoted by a different num-
ber of asterisks and are as follows: ****p ≤ 0.0001, ***p ≤
0.001, **p ≤ 0.01, *p ≤ 0.05. All experiments were re-
peated in triplicate with comparable results.
Results
Production of functional MT1-MMP in MCF-7 cells did not
result in increased migratory potential
We transiently transfected MCF-7 breast cancer cells
with wild-type untagged MT1-MMP cDNA and assessed
proMMP-2 activation, ERK activation, migration and in-
vasion (Fig. 1). qPCR and immunoblot analysis of MT1-
MMP mRNA and protein levels, respectively, of MCF-7
cells transiently transfected with MT1-MMP cDNA
showed that 24-h post-transfection these cells have very
high levels of MT1-MMP mRNA (~17,000 fold relative
to mock transfected cells) and produced predominately
the pro- but also active isoform, along with degradation
forms, of MT1-MMP protein (Fig. 1a). Gelatin zymogra-
phy analysis demonstrated that MCF-7 cells transiently
transfected with MT1-MMP are capable of activating
proMMP-2 after 24 h of incubation with MMP-2 CM, as
shown by the transition to the intermediate and active
isoforms of MMP-2. Parental MCF-7 cells, which do not
secrete endogenous proMMP-2, did not increase MMP-
2 production after transfection with MT1-MMP, as de-
termined by gelatin zymography (Fig. 1b, top gel).
Addition of proMMP-2 conditioned media to trans-
fected cells demonstrated that MT1-MMP overexpres-
sion activated proMMP-2 after 12 h of incubation,
shown by the presence of an intermediate band, whose
activation was enhanced by the addition of low levels of
TIMP-2 (100 ng/ml) that resulted in the presence of
more active MMP-2 isoform (Fig. 1b, bottom gel). Dif-
fering from published reports [24, 27, 28] we found no
difference in ERK activation (Fig. 1c) or migration and
invasion (Fig. 1d, ns > 0.05) in MCF-7 cells that pro-
duced functional MT1-MMP protein after transient
transfection.
To test whether the very high and heterogeneous
levels of MT1-MMP expression achieved using transient
transfection was a factor behind the discrepancies be-
tween our observation and other reports, we created
clonal MCF-7 cell lines that stably express significantly
different levels of MT1-MMP (Fig. 2). These cell lines,
MCF-7 MT1-MMP C1, C2, and C3 cells (hereby re-
ferred to as C1, C2 or C3 cells), significantly differ in
their stable expression of MT1-MMP transcript from
high (C1, ~2,500 fold compared to MCF-7 parental
cells), medium (C2, ~1100 fold) to low (C3, ~11 fold) as
determined by qPCR analysis (Fig. 2a). Immunoblot ana-
lysis of these MCF-7 MT1-MMP cell lines showed that
both pro- and active- isoforms of MT1-MMP protein
were detected in C1 cells, whereas the active isoform
was predominantly detected in C2 cells and no MT1-
MMP protein could be detected by immunoblot in C3
cells (Fig. 2b). Cell lines where active MT1-MMP was
detected via immunoblot (C1 and C2 cells) were capable
of activating proMMP-2 in a time-dependent manner,
and as expected this was enhanced by low levels of re-
combinant TIMP-2 (100 ng/ml), shown by a transition
to the intermediate form of MMP-2, which was com-
pletely inhibited by addition of BB94 (10 μM) (Fig. 2c).
Addition of diluted (1:100) TIMP-2 CM demonstrated a
greater enhancement of proMMP-2 activation by C1 and
C2 cells as shown by the presence of both intermediate
and active forms of MMP-2. Densitometry quantification
of a representative zymography with diluted TIMP-2
CM demonstrates that C2 cells have the highest ability
to activate proMMP-2, as shown by increased levels of
intermediate and active forms, despite not expressing
the highest level of MT1-MMP (Fig. 2c, bottom graph).
Active MMP-2 was not detected in C3 cells.
To confirm that C3 cells produced MT1-MMP protein
(not detectable by immunoblot) we used an imaging ap-
proach whereby cells were seeded on Oregon-green 488
gelatin coated coverslips and examined using immuno-
fluorescence for both MT1-MMP protein presence and
degradation of the underlying fluorescently labeled ECM
[42]. MDA-MB 231 breast cancer cells were also used in
this analysis to compare MCF-7, C1, C2 and C3 cells to
a cell line demonstrated to express naturally increased
levels of MT1-MMP (Fig. 3). Quantification of fields of
view acquired at 20× magnification demonstrated no de-
tectable cytoplasmic MT1-MMP immunological signal
nor gelatin degradation in parental MCF-7 cells. In
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Fig. 1 Transient overexpression of MT1-MMP in MCF-7 cells did not result in increased migration and invasion (a) qPCR, immunoblot, and gelatin
zymography analysis of MT1-MMP mRNA, protein levels, and proMMP-2 activation ability, respectively, of MCF-7 breast cancer cells transiently
transfected with MT1-MMP compared to mock transfected cells (control). Immunoblot analysis (AB6004) showed pro-, active, and degradation
forms of MT1-MMP protein in MT1-MMP transfected MCF-7 cells. β-actin was used as a loading control. Gelatin zymography analysis showed that
MCF-7 cells transiently transfected with MT1-MMP were capable of activating proMMP-2 after 24 h of incubation as shown by intermediate and
active forms of MMP-2. b Gelatin zymography analysis of MCF-7 cells transiently transfected with MT1-MMP and incubated for 12 h with serum-free
media (SF, top gel) or MMP-2 conditioned media (CM, bottom gel). Lanes 1 and 2: Controls showing proMMP-2 CM chemically activated by APMA.
Lanes 4 and 6: Recombinant TIMP-2 (rTIMP-2) was added at 100 ng/ml to enhance MT1-MMP-mediated proMMP-2 activation. c Immunoblot analysis
of MT1-MMP transfected cells showing phospho-ERK1/2 levels. Total ERK1/2 was used as a loading control. d Transwell migration and invasion assays
of MCF-7 cells transiently transfected with MT1-MMP. Number of migrated/invaded cells were normalized to control MCF-7 cells and expressed as a
mean percentage ± SEM. (ns, p > 0.05 by student’s t-test)
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contrast, 84 and 60 % of C1 and C2 cells displayed ECM
degradation (gelatin -), respectively, with approximately
20 % of these cells also displaying punctate cytoplasmic
immunological signal for MT1-MMP protein (Fig. 3, bar
graph). A low percentage of MT1-MMP C3 cells
(~1.5 %) showed ECM degradation, and a higher per-
centage (~3 %) showed a cytoplasmic MT1-MMP signal,
although these amounts were non-significantly different
than parental MCF-7 cells. Interestingly, in all condi-
tions where MT1-MMP was overexpressed, there were
cells that had degraded the underlying ECM that, para-
doxically, were devoid of MT1-MMP protein signal
(Fig. 3, white arrows). MDA-MB 231 breast cancer cells
were not capable of widespread cell-associated ECM
degradation, and only ~6 % of cells displayed cytoplas-
mic MT1-MMP signal. Taken together with the data in
Fig. 2, these analyses show that ECM degradation and
proMMP-2 activation is associated with elevated MT1-
MMP expression levels and immunodetection of MT1-
MMP protein (C1 and C2), consistent with other re-
ports. However, there is also an inconsistency when
comparing these results to C3 and MDA-MB 231 cells,
as C3 cells display no detectable levels of MT1-MMP
protein via immunoblot, but some C3 cells did degrade
the underlying ECM and displayed cytoplasmic MT1-
MMP protein via immunofluorescence. Additionally, the
pattern of ECM degradation and cytoplasmic MT1-
MMP protein in MDA-MB 231 cells is most consistent
with those of C3 cells, suggesting that cells that express
low levels of MT1-MMP acquire invasive capabilities,
despite reports that suggest high levels of MT1-MMP
are typically needed for such phenotypes [24, 27, 28].
Low levels of MT1-MMP expression combined with high
levels of TIMP-2 increased the migratory potential of
MCF-7 cells via the ERK pathway
As our analysis using transient transfection of MT1-
MMP demonstrated no change in cell migration, we
Fig. 2 MCF-7 cell lines producing high levels of MT1-MMP protein demonstrated TIMP-2-mediated proMMP-2 activation (a) qPCR analysis of MT1-MMP
mRNA from MCF-7 MT1-MMP cells lines that stably express different levels of MT1-MMP. Different letters indicate significant differences at p≤ 0.05 by
one-way ANOVA, Tukey’s post-hoc test. b Immunoblot analysis (AB51074) showing pro-, active, and degradation forms of MT1-MMP protein in MCF-7
MT1-MMP cell lines. β-actin was used as a loading control. c Gelatin zymography analysis of MCF-7 MT1-MMP cell lines incubated for 6 or 12 h with
either MMP-2 CM alone, or in combination with rTIMP-2 at 100 ng/ml, or rTIMP-2 and BB94 (10 μm). Cells were also incubated for 12 h in
MMP-2 CM supplemented with TIMP-2 CM diluted 1:100 in SF media (bottom). Bar graph shows densitometry quantification of MMP-2 isoforms from
representative zymography of MCF-7 MT1-MMP cell lines incubated with MMP-2 CM and TIMP-2 CM diluted 1:100
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wanted to further examine this migratory effect as well
as the potential role of ERK activation using our stable
cell lines that express lower levels of MT1-MMP than
transiently transfected cells. As others have previously
shown that TIMP-2 can modulate rapid ERK activation
by MT1-MMP expressing breast cancer cells [24, 25],
we utilized conditioned media (CM) that contained high
levels of TIMP-2, or ALA + TIMP-2 (a TIMP-2 mutant
that cannot inhibit MMPs enzymatic activity, but which
has been shown to still bind cell surface MT1-MMP and
upregulate ERK activation [24, 46]) to test this param-
eter. Analysis of these CMs via immunoblot showed that
high but equal levels of TIMP-2 and ALA + TIMP-2 are
present in the media, whereas reverse zymography ana-
lysis demonstrated that only TIMP-2 was capable of
inhibiting MMPs (Additional file 1: Figure S1a). Using
these CMs, we tested the ability of MCF-7 MT1-MMP
cell lines to sequester TIMP-2 from the media by treat-
ing these cells with diluted CM. TIMP-2 levels remained
equal after 15 min, but after 12 h of incubation TIMP-2
levels in the media decreased corresponding to the level
of MT1-MMP expression (Additional file 1: Figure S1b),
further confirming that these cells produced differing
levels of functional cell surface MT1-MMP. Quantifi-
cation of TIMP-2 protein in TIMP-2 CM via immuno-
blot was performed which demonstrated that
undiluted TIMP-2 CM contains approximately 10 μg/
ml TIMP-2 protein (Additional file 1: Figure S1c). The
proMMP-2 activation ability of MCF-7 MT1-MMP
cells was also tested in the presence of increasing
levels of TIMP-2 or ALA + TIMP-2 CM by gelatin
zymography and reverse zymography (Additional file 1:
Figure S1d). Only C1 and C2 cells were capable of acti-
vating proMMP-2, and this was enhanced by addition
of low levels of TIMP-2 (~100 ng/ml), but inhibited by
high levels of TIMP-2 (> ~1 μg/ml) [25, 47, 48], con-
sistent with the observations of others that TIMP-2 at
100 ng/ml is optimal for proMMP-2 activation by
MT1-MMP expressing cells [49]. ALA + TIMP-2 did
not enhance proMMP-2 activation in these cells con-
sistent with the requirement for both the N- and C-
terminal domains of TIMP-2 to act as an adapter for
proMMP-2 [20]. Taken together, this analysis con-
firmed the functionality of our TIMP-2/ALA + TIMP-2
CMs and demonstrated how MCF-7 cells producing
high levels of MT1-MMP protein follow the well-
Fig. 3 MCF-7 cell lines that express high levels of MT1-MMP demonstrated widespread ECM degradation (a) MCF-7, MT1-MMP cell lines, and MDA-MB
231 breast cancer cells were incubated on Alexa488 gelatin-coated coverslips for 24 h and processed for immunofluorescence to examine cytoplasmic
MT1-MMP protein and ECM degradation. Representative fields of view are shown at 20× (top panels) and 60× (bottom panels) magnification. Panels are
composed of an overlay showing the nuclei, F-actin, and Alexa488 gelatin signal (top) and the MT1-MMP signal with an inset of the Alexa488 gelatin
channel (bottom). White arrows indicate cells that have degraded the underlying gelatin but are devoid of MT1-MMP signal. Scale bars = 100 μm. Cells
in each sample positive for cytoplasmic MT1-MMP protein signal (MT1-MMP +) or devoid of underneath Alexa488 gelatin signal (Gelatin -)
were quantified per 20× fields of view and are shown as mean percentage of total cells per field of view ± SEM
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defined mechanism described for MT1-MMP/TIMP2
mediated activation of proMMP-2.
To then examine the level of ERK activation by MCF-7
MT1-MMP cell lines and the role of TIMP-2 in mediating
this process, cells were incubated in media containing
either 10 % FBS or in serum-free (SF) media containing
different dilutions of TIMP-2 or ALA + TIMP-2 CM.
Phospho-ERK levels were then examined using immuno-
blotting (Additional file 2: Figure S2) and quantified via
densitometry (Fig. 4a). In media containing 10 % FBS, only
C2 cells had a significantly higher level of phospho-ERK
compared to parental MCF-7 cells. A 12-h incubation
with TIMP-2 or ALA + TIMP-2 CM demonstrated a sig-
nificant decrease in ERK activation in C2 cells. In contrast,
a short 15 min incubation period with CMs demonstrated
a significant increase in ERK activation of C2 and C3 cells,
but not C1 cells, particularly with ALA + TIMP-2 treat-
ment. Additionally, short incubation periods with dilu-
tions of ALA + TIMP-2 CM showed that ERK activation
in C2 and C3 cells, but not C1 cells, is significantly upreg-
ulated by high levels of ALA + TIMP-2 protein. Overall,
analysis of phospho-ERK levels demonstrated that cells
expressing medium (C2) and low (C3) levels of MT1-
MMP demonstrate increased ERK activation that is up-
regulated by high levels of TIMP-2 (> ~ 200 ng/ml) and
independent of MMP inhibition.
We then examined how TIMP-2-mediated ERK activa-
tion related to the migratory potential of MCF-7 MT1-
MMP cell lines. A scratch closure assay over a span of
3 days demonstrated that only C3 cells closed the
scratch significantly faster than parental MCF-7 cells, in-
dicating increased migratory ability of C3 cells (Fig. 4b).
Migration was then examined using transwell assays
where the cells were incubated in SF media containing
TIMP-2 and ALA + TIMP-2 CMs in the upper compart-
ment and allowed to migrate towards the lower com-
partment containing 10 % FBS. TIMP-2 CM caused a
significant increase in the number of migrated C2 and
C3 cells, while ALA + TIMP-2 CM also caused a signifi-
cant increase in the number migrated C3 cells (Fig. 4c,
top). Higher dilutions of ALA + TIMP-2 CM showed a
similar trend whereby only C2 and C3 cells demon-
strated a significant increase in the number of migrated
cells (Fig. 4c, bottom). C1 cells, which express the high-
est level of MT1-MMP, demonstrated an inability to in-
crease migration potential when incubated with TIMP-2
CMs, and this was consistent with the lack of ERK acti-
vation upon TIMP-2 treatment in these cells.
To determine if the enhanced migratory ability of C3
cells was a result of the relatively low (11 fold) increase
in MT1-MMP expression, we transfected these cells
with a construct expressing an shRNA targeting MT1-
MMP, and selected two cells lines: C3 SH 1, a partial
knockdown which displayed a small but significant
increase in MT1-MMP mRNA level (1.8 fold change
p ≤ 0.01) as compared to parental MCF-7 cells, and C3
SH 2, a complete knockdown with 1.1 fold change (ns
p = 0.62). A cell line was also derived from C3 cells sta-
bly expressing a scrambled control shRNA (C3 SH
SCR) (Fig. 4d, top). Migration of these C3 cell line vari-
ants were assayed during incubation in SF media con-
taining TIMP-2 or ALA + TIMP-2 CM, or ALA +
TIMP-2 CM along with the ERK inhibitor U0126
(10 μM). Consistent with the previous transwell assays,
C3 and control C3 SH SCR cells were significantly
more migratory than parental MCF-7 cells when ex-
posed to high levels of TIMP-2 (> ~1 μg/ml), and this
correlated with ERK activation as ALA + TIMP-2/
U0126 incubation attenuated this migration (Fig. 4d,
bottom). This analysis also showed that complete
knockdown of MT1-MMP expression (C3 SH 2) inhib-
ited the TIMP-2-mediated increase in migration, indi-
cating that MT1-MMP is needed for enhancement of
migratory potential via TIMP-2. Surprisingly, C3 SH 1
cells, which express a small but significant (1.8 fold)
increase in MT1-MMP expression, demonstrated a
similar TIMP-2-mediated increase in migration via ERK
activation. Additionally, we attempted to knockdown
MT1-MMP expression in C1 and C2 cells to rescue mi-
gratory potential using the same approach, however, this
was unsuccessful using transfection of shRNA (not
shown) presumably because of the excessively high ex-
pression of MT1-MMP in these cells. Taken together, this
data demonstrated that TIMP-2 enhancement of migra-
tory potential is indeed dependent on MT1-MMP and
ERK activation, but low levels (1.8 -11 fold) of MT1-MMP
expression appear to be optimal to increase migratory
ability, whereas high (> ~1000 fold) MT1-MMP expres-
sion does not result in augmented cell migration.
Low levels of MT1-MMP expression and activity were
optimal for cell viability in serum free conditions
To analyze how MT1-MMP overexpression mediated
survivability and how this might explain the different
migratory potential of MCF-7 MT1-MMP cell lines, we
measured cell viability using CellTiter 96® AQueous One
Solution each day for 7 days during incubation in media
containing 10 % FBS or SF media, which represents the
two compartments in the transwell assay. In 10 % FBS,
C1 cells (high MT1-MMP level) showed a significantly
lower viability throughout the 7 days. Conversely C3
cells (low MT1-MMP level) were significantly more vi-
able from seeding until day 3 (Fig. 5a, top). Similarly, in
SF media C1 cells were less viable than parental MCF-7
cells from seeding until day 5, whereas C3 cells were sig-
nificantly more viable during this time (Fig. 5a, bottom).
After 6 days of incubation in SF media, all MT1-MMP
expressing cells were significantly more viable than
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Fig. 4 (See legend on next page.)
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Fig. 5 Low levels of MT1-MMP expression increased survivability of MCF-7 breast cancer cells to serum-free stress. a Viability of MCF-7 MT1-MMP cell
lines during incubation in media containing 10 % FBS (top) or serum free media (bottom) measured daily for 7 days using Celltiter96®. b Viability of
MCF-7 MT1-MMP cell lines and C3 cell line variants during incubation in SF media measured every 3 days for 9 days. Immunoblot analysis (bottom)
shows PH3 protein levels collected from MCF-7 MT1-MMP cell lines and C3 cell line variants incubated in SF media for 6 days. β-actin was used as a
loading control. Bar graph (right) shows densitometry analysis of PH3 levels. c Viability of MCF-7 MT1-MMP cell lines was measured after incubation for
6 days in SF media containing increasing concentrations of U0126, BB94, a furin inhibitor or an AKT inhibitor. Black asterisks show statistically significant
differences between the initial and day 6 viability within cell lines, and also differences between the day 6 viability of MCF-7 cells compared to MT1-
MMP expressing cell lines. Red asterisks indicate significant differences (p≤ 0.05) within cell lines between the day 6 viability in SF media compared to
the viability after 6 days of incubation with the different concentrations of the inhibitors
(See figure on previous page.)
Fig. 4 Low MT1-MMP/high TIMP-2 was optimal to promote migration and ERK activation in MCF-7 cells. a ERK activation in MCF-7 and MT1-MMP cells
after incubation for 12 h (top) or 15 min (bottom) in media containing 10 % FBS or different dilutions of TIMP-2 or ALA + TIMP-2 CM in SF media. b
Scratch closure migration assay of MCF-7 MT1-MMP cell lines monitored for 3 days. Shown are representative 10× fields of view. The white dotted lines
indicate the initial scratch size; red dotted lines indicate the scratch size at the respective day. Scale bars = 100 μm. Line graph on the right shows
scratch closure quantification that demonstrates significantly increased migratory potential of C3 cells. c Transwell migration assays of MCF-7 MT1-
MMP cell lines incubated for 48 h in TIMP-2, or ALA + TIMP-2 CM diluted 1:100 (top), or ALA + TIMP-2 CM in increasing dilutions (bottom). d (top) qPCR
analysis showing MT1-MMP mRNA from two cell lines derived from MT1-MMP C3 cells that stably express an shRNA construct targeting MT1-MMP,
and one cell line stably expressing a control scrambled shRNA construct. Different letters indicate significant differences at p≤ 0.05 by one-way ANOVA,
Tukey’s post-hoc test. Individual student’s t-tests comparing MCF-7 cells against the C3 SH 1 cell line is also shown. (bottom) Transwell migration assay
of MT1-MMP C3 cell lines incubated for 48 h in either TIMP-2 or ALA + TIMP-2 CM diluted 1:10, or ALA + TIMP2/U0126 (10 μm)
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MCF-7 cells indicating that MT1-MMP has an essential
role in mediating survivability during prolonged absence
of growth factors. To confirm that MT1-MMP was re-
sponsible for this increased viability during SF incuba-
tion, we repeated the analysis using the C3 knockdown
variants. Consistent with the previous analysis, only C3
cells had significantly higher viability at day 3, but by
day 6 and 9 all MT1-MMP expressing cell lines were
significantly more viable than MCF-7 cells (Fig. 5b). Via-
bility measurements of the C3 knockdown variants dem-
onstrated that MT1-MMP is responsible for enhanced
viability during SF incubation as C3 SH 2 cells, which
are MT1-MMP deficient similar to parental MCF-7
cells, are less viable than other cell lines at day 6, and
show the same viability as MCF-7 cells at day 9. To cor-
roborate these results, we also analyzed cell lysate from
all MCF-7 cell lines via immunoblot (Fig. 5b, bottom)
for the cell proliferative marker phospho-histone 3
(PH3), and quantified this using densitometry (Fig. 5b,
bar graph). All MCF-7 cell lines that expressed signifi-
cantly higher levels of MT1-MMP than MCF-7 cells
showed higher levels of PH3 after incubation in SF
media, particularly C2 cells, which accumulated high
levels of active MT1-MMP protein, and showed signifi-
cantly higher levels of PH3 than MCF-7 cells.
We then examined how inhibition of select signaling
pathways affected the viability of MCF-7 MT1-MMP cell
lines during prolonged SF incubation to gain insight into
the mechanism behind MT1-MMP-mediated survivabil-
ity. The chemical inhibitors U0126, BB94, furin inhibitor
II, and AKT inhibitor IV were used to examine their
effect on the viability of MCF-7 MT1-MMP cell lines
after 6 days of SF incubation. ERK inhibition and AKT
inhibition significantly decreased the viability of all
MT1-MMP expressing cells consistent with the observa-
tions of others [21, 24]. Furin inhibitor (which would in-
hibit intracellular activation of MT1-MMP) showed a
non-significant dose dependent decrease in the viability
of cells expressing MT1-MMP, a trend not seen in
MCF-7 parental cells, indicating that high levels of pro-
MT1-MMP likely negatively mediated viability. Unlike
all the other inhibitors that generally decreased viability,
low concentrations of BB94 trended to increase the via-
bility of all MT1-MMP expressing cells, especially C1
cells which displayed a significant increase in viability
after 6 days of SF incubation with 2.5 μM BB94 (Fig. 5c).
Taken together, this data demonstrated that MT1-MMP
mediated survivability to serum-free stress, but that ex-
cessive MT1-MMP proteolytic activity may be counter-
productive to increased viability. Furthermore, this
analysis also demonstrated that cell viability has to be
considered as a component to the pattern of migration
seen in transwell assays, as C3 cells which were the most
migratory are also the most viable, whereas in contrast
C1 cells were the least viable and migratory. Therefore,
it is difficult to delineate the relative contribution of
changes in cell proliferation or changes in migratory
capability to the difference in the number of cells quan-
tified in the bottom compartment of a transwell at the
endpoint of the assay.
MT1-MMP expression did not correlate with migratory
potential of breast cancer cells
Here we present evidence that high MT1-MMP overex-
pression (transient transfectants, C1 and C2 cells) does
not correlate with the migration of MCF-7 breast cancer
cells, as seen using the transwell migration assay, which
we showed also included a substantial cell viability com-
ponent. Increased MT1-MMP-mediated viability may
have yielded a higher number of cells in the transwell
compartments, which may have resulted in incorrect
conclusions about migratory potential if viability were
not considered. So to confirm that high MT1-MMP
overexpression (>1000 fold compared to MCF-7 cells)
does not result in increased migration, we used a live
imaging approach with automated migration quantifica-
tion of MCF-7 MT1-MMP cells that were stably ex-
pressing fluorescent zsGreen protein and incubated on
Alexa594 gelatin coated coverslips in control conditions
(0.1 % DMSO) (Fig. 6a, Additional files 3, 4, 5 and 6)
and with BB94 (10 μM) (data not shown). Automated
quantification using the ADAPT plugin for ImageJ soft-
ware [44] allowed us to track the migration of all indi-
vidual cells in three independent experiments, which
were then grouped according to their distance migrated
(Fig. 6b, Additional file 7). This analysis showed that
high MT1-MMP overexpression inhibited migration of
MCF-7 cells as a higher proportion of C1 and C2 cells
migrated a shorter distance from the initial point of
tracking compared to parental MCF-7 cells, as 53 % and
79 % of C1 and C2 cells, respectively, migrated more
than 25 μm, compared to 86 % of parental MCF-7 cells
that migrated the same distance. In contrast, C3 cells
did have increased migration ability compared to MCF-7
cells, as 92 % of C3 cells migrated more than 25 μm. Im-
portantly, this 6 % increase in migratory ability between
MCF-7 and C3 cells does not reflect the increase seen
using the transwell assays (20-100 % increase), confirm-
ing that there is a cell viability component underlying
the number of cells that transgressed to the bottom
transwell compartment. BB94 incubation did not affect
the migration of MCF-7 cells or C2 cells, but did alter
the migratory patterns of C1 and C3 cells. Inhibition of
MMP activity by BB94 decreased the migratory ability of
C3 cells as 92 % of cells migrated more than 25 μm in
control conditions compared to 66 % during BB94 incu-
bation. C1 cells, which express the highest level of MT1-
MMP and are the least migratory under control
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conditions, markedly improved their migratory potential
during BB94 incubation as 73 % of cells migrated more
than 25 μm (compared to 53 % in control conditions).
This migration data is consistent with the cell viability
assay during BB94 incubation, as C1 cells saw an aug-
mentation rather than decrease in viability and migra-
tion when MMPs were inhibited, suggesting that
excessive MMP activity is counterproductive to those
cellular processes. Analysis of the percentage of cells
that degraded the underlying ECM demonstrated a
time-dependent increase in ECM degradation correlated
to high MT1-MMP expression in C1 and C2 cells
(Fig. 6c), confirming functional MT1-MMP protein pro-
duction in these cells during the course of this assay.
Incubation with BB94 (10 μM) did not allow for degrad-
ation of the fluorescent gelatin by MT1-MMP expressing
cells (not shown). Taken together, this analysis dem-
onstrated that low levels of MT1-MMP expression
(11 fold compared to parental cells) are optimal for
increased migratory ability of MCF-7 breast cancer
Fig. 6 MT1-MMP activity is inversely correlated to the migratory potential of MCF-7 breast cancer cells (a) MCF-7 MT1-MMP cell lines stably expressing
zsGreen were seeded on Alexa594-gelatin coated coverlips in media containing 0.1 % DMSO (control) or 10 μm BB94 and incubated in a live imaging
chamber. Each sample was imaged at the same five stage positions every 10 mins for 20 h to visualize zsGreen cell movement and associated ECM
degradation (Additional files 3, 4, 5 and 6). Shown are stills of the Alexa594 gelatin channel and an overlay including the zsGreen cells at time 0 and
20 h post-seeding of the control sample (BB94 not shown). Scale bars = 100 μm. b Time-lapse videos from (a) were analyzed using the ADAPT plugin
for ImageJ and all individual cells tracked from each cell line were examined and grouped according to their migration distance from initial point of
tracking. c Percentage of cells per field of view from each cell line that degraded the underlying AlexaFluour594-gelatin at five different time points
Cepeda et al. Molecular Cancer  (2016) 15:65 Page 13 of 27
cells, whereas high MT1-MMP overexpression (>1000
fold) does not increase migration but allows for wide-
spread ECM degradation.
To further investigate the correlation between MT1-
MMP expression levels and the migratory potential of
cells, we extended our observations to MDA-MB 231
and HS578T breast cancer cells by first assessing en-
dogenous MT1-MMP levels in these cell lines. Both
MDA-MB 231 and HS578t cells expressed significantly
higher levels of MT1-MMP mRNA than MCF-7 cells
(~172 and ~100 fold, respectively), and are significantly
different from each other (Fig. 7a). Consistent with their
high levels of expression, MDA-MB 231 and HS578t
cells produce active MT1-MMP protein, and also have
higher levels of phospho-ERK than MCF-7 cells. Reverse
zymography analysis showed that MDA-MB 231 and
HS578t cells also produce higher levels of TIMP-2 pro-
tein compared to MCF-7 cells (Fig. 7b). Gelatin zymo-
graphy showed that MDA-MB 231 cells predominately
secreted proMMP-9, whereas HS578t cells secreted high
levels of proMMP-2 (Fig. 7c). Transwell migration assays
demonstrated that MDA-MB 231 and HS578t were
significantly more migratory than MCF-7 cells (Fig. 7d).
Importantly, HS578t cells were significantly more migra-
tory than MDA-MB 231 cells even though they express
lower levels of MT1-MMP.
We then tested how overexpression of MT1-MMP in
MDA-MB 231 cells affects the migration of cells that
natively express MT1-MMP and have endogenous mi-
gratory ability. MDA-MB 231 MT1-MMP stable cell
lines were created and three were selected which pro-
duce the isoforms of MT1-MMP shown via immunoblot
(Fig. 8a). MDA-MB 231 C1 cells produce pro- and ac-
tive- MT1-MMP, whereas MDA-MB 231 C2 and C3
produce predominantly active MT1-MMP at higher
levels than parental MDA-MB 231 cells. Transwell mi-
gration analysis of these MDA-MB 231 MT1-MMP cell
lines showed that overexpression of MT1-MMP signifi-
cantly decreased their migratory potential compared to
parental MDA-MB 231 cells (Fig. 8b). Viability of these
cell lines was analyzed in 10 % FBS (top) and SF media
(bottom) in the same manner as MCF-7 cell lines to
show that MT1-MMP overexpression significantly inhib-
ited viability, particularly of MDA-MB 231 C1 and C3
cells (Fig. 8c). Further, MDA-MB 231 C2 cells, which
accumulate high levels of active MT1-MMP protein, ex-
hibited increased viability in SF media and during pro-
longed incubation in 10 % FBS, which was consistent
with both our PH3 analysis of MCF-7 C2 cells, and with
their higher migration levels relative to the other MDA-
MB 231 MT1-MMP cell lines. Taken together these
analyses show that naturally increased MT1-MMP
Fig. 7 MT1-MMP expression does not correlate with increased migratory potential of breast cancer cells. a qPCR analysis of MT1-MMP mRNA levels
from MCF-7, MDA-MB 231, and HS578t breast cancer cells. b Immunoblot (AB51074) and reverse zymography analysis comparing MT1-MMP,
phospho-ERK and TIMP-2 protein levels between MCF-7, MDA-MB 231, and HS578t breast cancer cells. β-actin and total ERK1/2 were used as
loading controls. c Gelatin zymography analysis of MCF-7, MDA-MB 231, and HS578t breast cancer cells incubated in SF media for 12 h. Lane 1
shows proMMP-2 CM activated by MCF-7 C2 cells treated with TIMP-2 CM diluted 1:100 to show proMMP-2 activation as a result of TIMP-2/
MT1-MMP. d Transwell migration assay of MCF-7, MDA-MB 231, and HS578t breast cancer cells incubated in SF media for 24 h
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expression in transformed cancer cells (MDAMB-231,
HS578t cells) does result in enhanced migration, but this
is not the case for experimental MT1-MMP overexpres-
sion (MT1-MMP cell lines), as increasing overexpression
of MT1-MMP decreases rather than enhances the mi-
gratory potential of breast cancer cells.
Low level of MT1-MMP expression mediated a protrusive
phenotype in 3D culture
As our work using in vitro 2D culture demonstrated that
increased, but relatively low levels of MT1-MMP expres-
sion were optimal for enhanced survivability and migra-
tion, we subsequently examined how these observations
translated to ex vivo 3D culture. In this culture system
breast cancer cells are embedded in Matrigel, whose
composition resembles the components of a natural BM,
and as such mimics a more physiologically relevant 3D
environment [43]. MCF-7 MT1-MMP cell lines were
embedded in Matrigel and cultured for 5 days in media
containing 10 % FBS. During this time, cell morphology
was monitored using DIC microscopy to examine how
MT1-MMP expression affected cell behavior. Non-
invasive MCF-7 cells have been shown to form and
remain in circular colonies during 3D culture [50]
(Fig. 9a, white arrow), which resemble the acini-like
structures that normal breast cells form that are repre-
sentative of the terminal ductal lobular unit (TDLU) in
the human breast [51]. In contrast, invasive MDA-MB
231 cells lose this circular morphology and develop into
an interconnected network within the Matrigel (Fig. 10a,
red arrow).
During 3D culture, C1, C2 and C3 cells do not form
an interconnect network as seen with MDA-MB 231
cells. Instead, their colonies remained circular but dis-
play two distinct phenotypes; disseminations - distinct
particles being released from circular colonies (Fig. 9a,
green arrow), and short dynamic protrusions emerging
from colonies (Fig. 9a, red arrows), which were con-
firmed using time-lapse microscopy (Additional file 8:
Figure S3a, Additional files 9, 10, 11 and 12). Compari-
son of these morphological features between cell lines
were blindly quantified per 10× magnification fields of
view each day for 5 days and normalized to the number
of circular colonies per field of view (Fig. 9a, line
graphs). This quantification demonstrated that MCF-7
expressing high levels of MT1-MMP (C1 and C2) had
significantly higher number of disseminations per colony
than MCF-7 and C3 cells, particularly C1 cells which
showed a time-dependent release of particles (Additional
file 10). In contrast, the number of protrusions per col-
ony at day 5 was inversely proportional to MT1-MMP
expression, as C2, and especially C3 cells had signifi-
cantly more protrusions per colony, whereas C1 cells
had a significantly lower number of protrusions than
MCF-7 cells. Immunofluorescence analysis of these
MCF-7 MT1-MMP cell lines (Fig. 9b), confirmed that
Fig. 8 Overexpression of MT1-MMP in MDA-MB 231 cells negatively affected migration and viability (a) Immunoblot analysis (AB6004) showing
pro-, active, and degradation forms of MT1-MMP in MDA-MB 231 breast cancer cells and three MDA-MB 231 cell lines expressing different levels
of MT1-MMP. β-actin was used as a loading control. b Transwell migration assay of MDA-MB 231 MT1-MMP cells incubated in SF media for 12 h.
c Viability of MDA-MB 231 MT1-MMP cell lines during incubation in media containing 10 % FBS (top) or serum free media (bottom) measured
daily for 7 days using Celltiter96®
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Fig. 9 MT1-MMP overexpression in MCF-7 cells induced loss of colony organization and was inversely correlated with a protrusive morphology in 3D
culture. a (top) MCF-7 MT1-MMP cells were embedded in Matrigel and imaged every day for 5 days at 10× magnification. Shown is a representative field
of view of each cell line at day 5, and indicated inset images which show the cell features quantified: Circular colonies (white arrow), disseminations around
colonies (green arrow), or protrusions emanating from colonies (red arrows). Scale bars = 100 μm. (bottom) Five z-stacks per cell line were acquired every
day for 5 days and disseminations and protrusions were quantified per colony for each cell line. b Representative 3D volume views of immunofluorescence
analysis after MCF-7 MT1-MMP cells were embedded in Matrigel for 5 days. Samples were imaged using confocal microscopy at 60× and are displayed as
overlays showing MT1-MMP signal (green), DAPI (blue) and Alexa633 phalloidin (red) channels. Scale bars = 100 μm. White arrow show circular colonies.
Green arrows displays single cells that disseminated from the nearby colonies and show MT1-MMP protein. Red arrow shows an F-actin protrusion
emanating from a circular colony (c) Single cells, F-actin disseminations, F-actin protrusions, and zsGreen protrusions were quantified from 20× magnification
3D volumes acquired after MCF-7 MT1-MMP cell lines stably expressing zsGreen were embedded in Matrigel for 5 days. The 60× magnification 3D volume
of MT1-MMP C3 cells shows both F-actin (red arrow) and zsGreen (blue arrow) protrusions emerging from a colony. Scale bars = 100 μm
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while MCF-7 colonies retained circularity during 3D
culture (white arrows), C1 and C2 cells had clear
disorganization of colony structure with released cell
fragments (disseminations) containing MT1-MMP pro-
tein (green arrows). In contrast, C3 cells demonstrated
long F-actin protrusions emerging from circular colonies
(red arrows), consistent with the protrusive phenotype.
To further characterize this novel dissemination
phenotype mediated by MT1-MMP, the cellular compos-
ition of released fragments was examined by repeating
the immunofluorescence analysis with the zsGreen
MCF-7 tagged cells. The fluorescently tagged variants
were used to provide information about the origin of
morphological structures as zsGreen accumulated in the
cytoplasm and could be used to better visualize the ori-
gins of disseminations or protrusions. The number of
single cells (marked by DAPI), F-actin disseminations, F-
actin protrusions, and zsGreen protrusions were quanti-
fied per colony from 20× magnification 3D volume views
(Additional file 8: Figure S3b). This quantification dem-
onstrates that the disseminations are likely enucleated
cells, as C1 cells show significantly higher levels of single
cells (0.18/colony) and F-actin disseminations (0.67/col-
ony) (Fig. 9c), which added together represented a dens-
ity of ~0.85/colony, similar to the ~1 dissemination/
colony seen by day 5 in our DIC microscopy analysis
(Fig. 9a). In contrast, C3 cells demonstrate higher dens-
ity of F-actin (0.65/colony) and zsGreen protrusions
(0.15/colony), which when added together represent a
density of ~0.8/colony similar to the ~1 protrusion/col-
ony seen by day 5 in our DIC analysis, confirming that
these cells demonstrate a protrusive morphology in 3D
culture. Volume views at 60× magnification also showed
C3 colonies (Fig. 9c) that demonstrated many zsGreen
Fig. 10 MT1-MMP overexpression inhibited the protrusive morphology of MDA-MB 231 breast cancer cells in 3D culture. a (top) MDA-MB 231 MT1-MMP
cells were embedded in Matrigel and imaged every day for 5 days at 10× magnification. Shown are representative fields of view of each
cell line at day 5 and a respective inset. Red arrow shows a portion of the protrusive network MDA-MB 231 cells form in 3D culture. White arrows show
MDA-MB 231 MT1-MMP cell colonies that have retained circularity after 5 days in 3D culture. Scale bars = 100 μm. (bottom) Five z-stacks per cell line
were acquired every day for 5 days and disseminations and protrusions were quantified per colony for each cell line. b Representative 3D volume
views of immunofluorescence analysis after MDA-MB 231 MT1-MMP cells were embedded in Matrigel for 5 days. Samples were imaged using confocal
microscopy at 60× magnification and are displayed as overlays showing MT1-MMP signal (green), DAPI (blue) and Alexa633 phalloidin (red) channels.
Scale bars = 100 μm. Red arrow shows protrusive MDA-MB 231 cells, whereas green arrows show circular colonies in MDA-MB 231 MT1-MMP cell lines
that are positive for MT1-MMP protein signal. Scale bars = 100 μm
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protrusions (blue arrow) that emerged from existing F-
actin protrusions (red arrow). These protrusions are
indicative of invadopodia, which are characterized by ex-
tension of the cell body due to F-actin polymerization,
and subsequent F-actin retraction to result in a protru-
sion devoid of F-actin [35].
To corroborate our 3D observations with the MCF-7,
C1, C2 and C3 cell lines, we performed a similar analysis
with MDA-MB 231 MT1-MMP cell lines. MDA-MB 231
cells progressively lost circular morphology and devel-
oped into an interconnect network of cells within the
Matrigel (Fig. 10a, red arrow), represented by a signifi-
cantly higher number of protrusions per colony (~25)
than MCF-7 cells. In contrast, all MDA-MB 231 cells ex-
pressing MT1-MMP showed a significant inhibition to
form networks in 3D culture and instead retained a large
proportion of circular colonies (Fig. 10a, white arrows).
As well, MDA-MB 231 MT1-MMP cells demonstrated a
nonsignificant increase in the number of disseminations
(~0.4 dissemination/colony), although it was compara-
tively lower than in MCF-7 MT1-MMP cells. Immuno-
fluorescence analysis of F-actin and nuclear structures in
3D culture confirmed these observations and showed
that parental MDA-MB 231 cells formed an extensive
cellular network, whereas MDA-MB 231 MT1-MMP
cells retained circular colonies marked by MT1-MMP
protein (Fig. 10b, green arrows). Taken together, this
ex vivo analysis demonstrated that low MT1-MMP ex-
pression mediated a protrusive phenotype in 3D culture,
shown by C3 (Fig. 9a) and MDA-MB 231 cells (Fig. 10a),
whereas high levels of MT1-MMP expression (C1, C2,
and MDA-MB 231 MT1-MMP cells) inhibited the ability
to form protrusive networks in 3D culture and instead
resulted in abnormal release of cell fragments.
Low levels of MT1-MMP expression mediated a tumorigenic
metastatic phenotype in vivo
We then tested the in vivo implications of our in vitro
observations by using the ex ovo chicken embryo [52]
and zsGreen expressing MCF-7 C1, C2, and C3 cell
lines. These cells, along with zsGreen MDA-MB 231
cells, were suspended in Matrigel and implanted into the
ChorioAllantoic Membrane (CAM) of day 9 ex ovo
chicken embryos [45]. Eight days post implantation the
resulting xenograft was visualized using a fluorescent
stereoscope to assess vascularization of the formed
tumour. No MCF-7 or C1 tumours were scored as vas-
cularized, whereas a minority (2/14) of C2 tumours
demonstrated vascularization by vessels of the chicken
embryo (Fig. 11). In contrast, the majority of C3 (14/15)
and MDA-MB 231 (15/16) tumours were vascularized,
shown by the presence of non-fluorescent vessels
present within the zsGreen tumour (Additional file 13:
Figure S4, white arrow).
The metastatic potential of these cell lines was subse-
quently examined by direct intravenous injection of
zsGreen MCF-7 C1, C2, and C3 cell lines into the vascu-
lature of day 14 chicken embryos, followed by assess-
ment of extravasation efficiency 24 h post-injection [37].
Extravasation out of the vasculature is a necessary step
that precedes metastatic colony formation and as such
has been shown to directly correlate with metastatic po-
tential [4]. MCF-7 and C1 cells, which express the high-
est level of MT1-MMP, demonstrate poor extravasation
efficiency, as < 5 % of cells were able to extravasate after
24 h (Fig. 12a). C2 cells showed a higher but non-
significant increase in percentage of extravasated cells
(~8 %), whereas C3 cells, which express low levels of
MT1-MMP, displayed a significant increase in extravasa-
tion efficiency (~15 %) compared to all other MCF-7 cell
lines. Orthogonal sections of extravasated C1 and C3
cells acquired using confocal microscopy at 60× magnifi-
cation showed that C1 cells are capable of extravasating
out of the CAM vasculature (Fig. 12b) but display mem-
brane blebbing (white arrow) and cell fragment release
(green arrow), reminiscent of our observations in 3D
culture (Fig. 9). In contrast, C3 cells exhibited a uniform
morphology as they extravasated into the stromal space
(blue arrows) and contained cell protrusions trailing
from the CAM capillary bed into the stroma (Additional
file 14, red arrow), suggesting that these cells formed
invadopodia in vivo.
Metastatic 21 T breast epithelial cell line produces
undetectable levels of MT1-MMP protein
To extend and corroborate our observations that low
levels of MT1-MMP are optimal to promote metastatic
features in 3D culture and in vivo, we assayed via immu-
noblot the level of MT1-MMP protein in the 21 T series
cell lines. These cells were isolated from a single patient
and represent a mammary tumor progression series that
mimic specific stages of breast cancer progression [39, 53]
(atypical ductal hyperplasia -21PT-ADH, ductal carcinoma
in situ -21NT – DCIS and invasive mammary carcinoma-
21MT-1- IMC) (Fig. 13). Assaying MT1-MMP protein
levels in these cell lines demonstrated that ADH and
DCIS variants produced active MT1-MMP, with the non-
invasive DCIS cells producing higher levels of MT1-MMP
protein. Direct comparison to the MCF-7 MT1-MMP cell
lines showed that C1 and C2 cells produced more active
MT1-MMP than ADH or DCIS 21 T cells. In contrast,
21MT-1 cells, which represent an invasive mammary
carcinoma, produced undetectable levels of MT1-MMP
protein as determined by immunoblot, similar to C3 cells.
The 21MT-1 IMC cells have been show to possess meta-
static qualities in 3D culture and in vivo when compared
to the non-invasive variants [39], consistent with our ob-
servations that low levels of MT1-MMP are representative
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of metastatic breast cancer. Taken together, the observa-
tions in our study demonstrate that low levels of MT1-
MMP expression are optimal for tumorigenicity and
metastatic potential in vivo, and importantly, that abnor-
mally high MT1-MMP overexpression correlated with a
decrease, rather than enhancement of tumorigenic fea-
tures (see schematic representation Fig. 14).
Discussion
In this study, we utilized overexpression of functional
MT1-MMP in MCF-7 and MDA-MB 231 breast cancer
cells and demonstrated how overexpression corresponds
to proMMP-2 activation and ECM degradation, but
inversely correlates to migratory potential, protrusive
phenotype in 3D culture, and tumorigenic features
in vivo. Instead we showed that high overexpression of
MT1-MMP negatively affects cell viability, and causes an
abnormal loss of colony structure and cell fragment re-
lease in 3D culture that translates to decreased tumori-
genic potential in vivo. We also demonstrated using the
human 21 T cell lines mammary tumour progression
series that breast cancer cells which mimic an invasive
mammary carcinoma (IMC) are better represented by
low, rather than high, levels of MT1-MMP protein. Our
data is at odds with the notion that high MT1-MMP ex-
pression is crucial for tumour progression, as numerous
studies report that MT1-MMP overexpression is associ-
ated with enhanced migratory ability and tumourigene-
city [17, 26, 27, 33, 34, 54], although there is also
evidence in agreement with our study which shows that
high MT1-MMP overexpression is insufficient to in-
crease metastasis of human cancer cells [31]. Addition-
ally, despite the mounting evidence demonstrating that
MMPs have a direct role in basement membrane deg-
radation in vitro, there is no evidence to date that shows
this is the case in vivo, and instead such studies suggest
that the role of MMPs may not be related to ECM deg-
radation but rather proteolysis of non-ECM substrates
(Reviewed in [9]).
Here, using MCF-7 clonal cell lines stably expressing
untagged MT1-MMP, we show that migration, as shown
by a scratch closure assay and by time-lapse microscopy
of cells on fluorescent substrate, is dependent on levels
of MT1-MMP, with high levels decreasing migratory
Fig. 11 MCF-7 MT1-MMP C3 cells displayed high tumorigenic potential when implanted onto the avian embryo CAM. MCF-7 MT1-MMP cell lines
and MDA-MB 231 cells stably expressing zsGreen were implanted into the CAM of day 9 ex ovo chicken embryos and visualized 8 days
post –implantation using a fluorescence stereoscope to analyze tumor vascularization. Displayed are representative bright field images
showing the area of implantation on the embryo, and respective fluorescent images showing the zsGreen channel. The white boxes outline the insets
showing vascularization of the MT1-MMP C3 and MDA-MB 231 tumours. Bar graph shows percentage of tumours that were vascularized (N≥ 11).
Scale bars = 2 mm
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ability and low levels promoting it. We also demonstrate
that migration changes seen using transwells involve a
substantial cell viability component, where high MT1-
MMP overexpression negatively affects viability and low
levels enhances it. This viability difference likely contrib-
uted to the magnitude of migration augmentation be-
tween transwell and other assays. Studies that show an
increase in cancer cell migration as a result of MT1-
MMP overexpression demonstrate migration enhance-
ment ranging from 50 -500 % [26–28], whereas others
show a requirement of TIMP-2 for MT1-MMP mediated
migration enhancement [24, 25]. These reports do not
agree on a specific mechanism, except general ERK acti-
vation. In contrast, there are studies demonstrating that
MT1-MMP overexpression does not increase migration
of breast cancer cells [55], and also that MT1-MMP
overexpression decreases ERK activation in cancer cells
[56]. In the latter study, the authors demonstrated that
MT1-MMP overexpression in various cancer cell lines,
including MCF-7 cells, downregulates ERK activation
and migration in response to FGF-2, which is consistent
with our findings using cells that express high levels of
MT1-MMP. Other studies have provided strong mech-
anistic evidence that MT1-MMP is involved in apoptosis
protection [21] and viability enhancement via HIF1α
stabilization [23, 57], which are in line with our observa-
tions that MT1-MMP enhances viability during serum-
free incubation.
A striking finding of our in vitro analysis regarding the
relationship between MT1-MMP expression and migra-
tion was that the most migratory cells were the ones
which had a low MT1-MMP:high TIMP-2 ratio. Of the
MCF-7 MT1-MMP cell lines used, C3 and C3 SH 1 cells
displayed low MT1-MMP levels (11 and 1.8 fold change
vs parental MCF-7 cells, respectively), and their migra-
tion ability was greatly enhanced when the levels of
TIMP-2 increased, especially C3 SH 1 cells. MDA-MB
231 MT1-MMP cell lines displayed the same trend
whereby MT1-MMP overexpression with no change in
TIMP-2 expression (data not shown) shifted the ratio in
favor of excess MT1-MMP, and thereby causing a de-
crease in migratory potential. Similarly, analysis of the
natural migration potential of MCF-7, MDA-MB 231,
and HS578t cells is consistent with this relationship to
TIMP-2, as HS578t cells were the most migratory and
displayed the highest level of TIMP-2 relative to MT1-
MMP. Noteworthy in this analysis was also the observa-
tion that MDA-MB 231 cells displayed the highest ERK
activation, but were not the most migratory. This was
consistent with our comparison of MCF-7 C2 and C3
cells, whereby C2 cells showed the highest ERK activa-
tion but were less migratory than C3 cells, which dis-
played comparatively lower ERK activation even in the
presence of high levels of TIMP-2.
Although TIMP-2 is a natural MMP inhibitor and as
such has attracted therapeutic interest along with syn-
thetic MMP inhibitors [10, 58–62], neither have shown
value in clinical trials [63]. Instead, some have suggested
that high TIMP-2 levels may promote tumourigenecity
[24, 64, 65], which has been strengthened by the associ-
ation of high TIMP-2 levels with poor prognosis in
Fig. 12 MT1-MMP expression was inversely correlated to the
extravasation efficiency of MCF-7 breast cancer cells in vivo. a
Representative 3D volume views at 20× magnification of MCF-7
MT1-MMP cells stably expressing zsGreen 24 h-post intravenous
injection into the chicken embryo CAM vasculature. Shown is an
overlay displaying the zsGreen cells (green) and CAM vasculature
and underlying stromal vessels labeled using lectin-rhodamine
(red), and the isolated zsGreen channel. Scale bars = 100 μm. Bar
graph shows quantification of extravasation efficiency of MCF-7
MT1-MMP cell lines 24 h post-injection. b Orthogonal views of
Z-stacks acquired using confocal microscopy at 60× of MT1-MMP
C1 and C3 cells 24 h post-injection showing the top of the CAM
capillary bed (top) and the underlying stroma (bottom). Extravasated
MT1-MMP C1 cells display loss of cell fragments (green arrows) and
membrane blebbing (white arrow), whereas MT1-MMP C3 cells
extravasate to below the CAM with uniform morphology (blue
arrows) and are capable of forming invasive protrusions in the
stroma (red arrow). Scale bars = 100 μm
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various human cancers, including breast [66–71]. Al-
though this association between an MMP inhibitor and
poor cancer prognosis may be paradoxical, we describe
here that while TIMP-2 regulation of MT1-MMP activ-
ity is complex, as exemplified by MDA-MB 231 and
HS578t cells, high TIMP-2:low MT1-MMP ratios in
these cells correlate with their migratory potential, and
also with their lack of gelatin degradation and inhibited
proMMP activation ability. Despite the fact that MDA-
MB 231 and HS578t cells naturally express MT1-MMP,
MMP-2, and −9, the extracellular gelatinases are pre-
dominately found in their pro-forms yet to be activated.
As MT1-MMP activity is pivotal in gelatinase activation
[20], this indicates that MT1-MMP present in these cells
is inhibited, likely by TIMP-2. This is consistent with
lack of gelatinase activity of C3 cells, and in stark
contrast to C1 and C2 cells, suggesting that cells with
non-physiologically high MT1-MMP exhibit excessive
proteolysis which may be counterproductive to migra-
tion and cell viability. This is corroborated both with the
rescued serum free viability and migration of C1 cells as
a result of BB94 treatment, and with the role of TIMP-2
in mediating survivability under serum free conditions
as shown by others [21]. Since MT1-MMP is a
Fig. 13 Metastatic human 21 T breast cancer cells showed undetectable levels of MT1-MMP protein similar to MCF-7 C3 cells. Protein lysate from
human 21 T breast cancer cell lines, which represent a progression series from atypical ductal hyperplasia (21PT-ADH), to ductal carcinoma in situ
(21NT – DCIS), to invasive mammary carcinoma (21MT-1- IMC), were analyzed via immunoblot for MT1-MMP protein levels along with the MCF-7
MT1-MMP cell lines. The blots were probed with either AB6004 (top) or AB51074 (bottom) and shown as the normal exposure and as transformed
versions to clearly show banding pattern. Asterisks indicate MT1-MMP isoforms (green – pro form, red- active form, orange – degradation forms).
β-actin was used as a loading control
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proteolytic enzyme that can cleave and alter the function
of many ECM and non-ECM proteins crucial for
proper cell behavior [18], it is logical that such a po-
tent protease with wide substrate specificity would be
under tight control by TIMP-2 to appropriately medi-
ate cell behaviour.
Maden and Bugge (2015) analyzed the last two de-
cades of literature to examine if there was a consensus
regarding the cellular source of MMPs (including MT1-
MMP) in human cancers and whether they were pre-
dominately stromal or cancer cell derived. These authors
noted that publications were widely inconsistent in
regards to the cellular source of MMPs, particularly
when immunodetection was involved. Only when in situ
hybridization was used was there a consensus seen that
MMPs were likely stromal cell derived [29]. The authors
proposed reasons for these difficulties, one being that
there is likely inherently low expression of MMPs in
cancer cells compared to stromal cells making immuno-
detection technically challenging.
We believe that unreliable immunodetection reagents
(discussed in [72]) is a major contributing reason as to
why there is such inconsistency when assessing the
abundance of MMPs in human cancers and their value
as prognostic markers. In our study, we initially experi-
enced difficulties assessing immunoblots for MT1-MMP,
which could only be correctly interpreted after examin-
ing the immunological banding pattern for MT1-MMP
expressing MCF-7 and MDAMB-231 cell lines and
probing with two different primary antibodies against
MT1-MMP (Additional file 15: Figure S5). To
strengthen the idea that improper immunodetection of
MT1-MMP protein can lead to incorrect conclusions,
we highlight our (lack of ) immunodetection of MT1-
Fig. 14 Schematic overview of MT1-MMP expression levels and associated changes in substrate degradation and cell migration in 2D culture,
phenotypes in 3D culture, and tumourigenesis in vivo. Schematic representation of the findings of this study showing cell phenotypes across 2D
and 3D culture platforms and in vivo. Legend describing molecular components in diagrams is shown at the top, and fold change relative to
MCF-7 parental cells is in the brackets to the right of the bolded titles. MT1-MMP deficient breast cancer cells, such as MCF-7 cells, are incapable
of proMMP-2 activation or ECM degradation, and show low migration and viability during serum-free incubation. These cells retain a circular
morphology in 3D culture, and do not form vascularized tumours nor display high extravasation efficiency in vivo. Cells expressing high levels of
MT1-MMP are capable of proMMP-2 activation and widespread ECM degradation, have increased survivability to serum-free stress, but do not
demonstrate increased migration in 2D experiments. In 3D culture, these cells demonstrate a dissemination morphology and cell fragment release
mediated by MT1-MMP. Despite MT1-MMP protein production and associated substrate degradation, these cells are unable to form vascularized
tumours or increase their extravasation efficiency in vivo. Cells expressing low levels of MT1-MMP do not demonstrate proMMP-2 activation or
widespread ECM degradation, but do show increased migratory potential, and high viability during serum-free incubation. These cells demonstrate a
protrusive morphology in 3D culture, form vascularized tumours in vivo, and have significantly increased extravasation efficiency. Data figures within
this study that correspond to the diagrams within this model are in red text
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MMP in MCF-7 breast cancer cells. We strongly believe,
as suggested by others, that MCF-7 cells are MT1-MMP
deficient [24, 33], particularly because it has been shown
that the MT1-MMP promoter in these cells is hyper-
methylated and thus transcriptionally repressed [73]. Yet
despite this observation, published studies claim to
detect both pro- and active MT1-MMP protein via
immunoblot in these cells [34, 74], which could be due
to incorrect identification of the cell line used for experi-
mentation, or lack of stringency when conducting
immunodetection. As can be seen from our immunoblot
data, usage of a polyclonal antibody against MT1-MMP
resulted in a non-specific signal that could easily be mis-
interpreted as pro- and active MT1-MMP in MCF-7
cells. Furthermore, in the study done by Köhrmann
et al., although the authors reported MT1-MMP protein
in MCF-7 cells, they were not able to detect MT1-MMP
protein from clinical samples via immunoblot. However,
they were able to detect MT1-MMP protein in tissue
sections from tumour samples and not from normal tis-
sues. Studies that are internally inconsistent regarding
MT1-MMP protein detection, and which contain clinical
samples, can create confounding conclusions regarding
the role of MMPs in cancer and are in agreement with
the observations of Madsen and Bugge regarding the
discrepancies of the source of MMPs in human cancer.
Additionally, visualizing MT1-MMP protein at a cellular
level using immunofluorescence may also lead to similar
immunodetection problems. Lodillinsky et al. recently
implicated the p63/MT1-MMP axis in the transition
from in situ to metastatic breast cancer, reporting that
MT1-MMP protein is present during BM invasion of
MCF10DCIS.com xenografts. However, with the know-
ledge that MT1-MMP is localized to distinct specialized
regions of the cell membrane to initiate invasion (inva-
dopodia), we question such immunofluorescence data
that show MT1-MMP protein is present throughout
the cell membrane of every cell in the xenograft, re-
gardless of whether it is in physical proximity to invade
the BM.
To assess the physiological relevance of observed
levels of MT1-MMP expression in this study, we com-
pared these to recently reported MT1-MMP mRNA
levels in malignant and non-malignant human breast tis-
sues. The reported increase in MT1-MMP mRNA levels
between malignant tissues and normal tissues ranged
between ~1.7 and ~3.2 fold [75–77]. Similarly, a pio-
neering study used MDA-MB 231 variants that pro-
duced constitutively active scr kinase, which is known to
be upregulated during cancer progression [35]. These
MDA-MB 231 variants generated significantly more
MT1-MMP containing invadopodia. Analysis of MT1-
MMP mRNA changes between control and constitu-
tively active src kinase cells demonstrated a ~1.8 fold
change increase in MT1-MMP mRNA, which the au-
thors describe as a mechanistically meaningful increase
in MT1-MMP expression. Therefore, the physiological
relevance of extreme changes in expression levels, such
as our ~17,000 fold change in MT1-MMP mRNA seen
in our transient transfectants, or ~1500 fold change in
stable cell lines, would be difficult to reconcile with
primary human breast cancers which have a ~1.7 to
3.2 fold change in MT1-MMP mRNA expression.
Additionally, in line with our idea that immunological
reagents of MT1-MMP may be unreliable, if normal
non-malignant tissues do not contain detectable levels
of MT1-MMP [17, 34] and cancerous tissues demon-
strate only a ~1.7 to 3.2 fold increase in MT1-MMP
mRNA, then is it reasonable that a transcriptional in-
crease of that magnitude would be difficult to immu-
nodetect at the protein level.
Consistent with the conclusion of the importance of
low levels of MT1-MMP expression are the observations
seen in our physiologically relevant ex vivo and in vivo
experiments, whereby MCF-7 cells expressing low levels
of MT1-MMP (C3) demonstrated behavior consistent
with the role of MT1-MMP during cancer progression.
C3 cells have increased protrusive morphology in 3D
culture and this is contrasted with MCF-7 cells overex-
pressing high levels of MT1-MMP which show reduced
protrusive ability and increased cell fragmentation. Simi-
larly, C3 cells were tumorigenic and showed metastatic
potential in vivo, unlike C1 and C2 cells, which is
consistent with studies that knock down MT1-MMP
expression and show inhibition of these parameters.
Additionally, analysis of MT1-MMP protein levels in the
21 T cell lines mammary tumour progression series
demonstrated that breast cancer cells which represent
ADH and DCIS mammary tumours produce high levels
of active MT1-MMP protein, whereas invasive 21MT-1
IMC cells produce undetectable levels of MT1-MMP, an
observation that is consistent with our findings using
MCF-7 C3 cells and our overall conclusion that low
levels of MT1-MMP may better represent metastatic
cancer. A similar study using the HMT-3522 epithelial
cell series yielded results consistent with our analysis of
MT1-MMP levels in 21 T cells, as these authors ana-
lyzed microarray data to show that MMP-9, −13,-15 and
−17, but not MT1-MMP, were functionally significant in
the acquisition of invasiveness [78].
Interestingly, the observation that DCIS 21 T cells pro-
duced high levels of active MT1-MMP in comparison to
their IMC counterparts is similar to the 3D culture
phenotype of our MDA-MB 231 cells overexpressing
MT1-MMP. In our study, parental MDA-MB 231 cells,
which are naturally invasive, readily form irregular net-
works in 3D culture in contrast to non-invasive cell lines
that partially maintain polarity and form acini similar to
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the TDLU in the human breast (eg MCF-7 cells). It was
surprising to us to that overexpression of MT1-MMP in
invasive MDA-MB 231 cells reverted their phenotype in
3D culture towards a DCIS-like morphology where the
ability to form networks in matrigel 3D culture was re-
stricted and a higher proportion of these cells retain
acini-like colonies. The reversion of MDA-MB 231 cells
to a DCIS-like phenotype in 3D culture as a result of
MT1-MMP overexpression is consistent with our ana-
lysis of MT1-MMP protein levels in the 21 T cell lines
whereby DCIS (21NT) cells produce more active MT1-
MMP and predominately form acini in 3D culture, and
IMC (21MT-1) cells produce less MT1-MMP protein
and display invasive 3D behavior [39], similar to our
MT1-MMP MDA-MB 231 cells and parental MDA-MB
231 cells, respectively.
Taken together, this study shows that a physiologically
relevant increase in MT1-MMP expression is at best
represented by a 1.8 to 11-fold change compared to nor-
mal tissue. Additionally, although abnormally high levels
of MT1-MMP overexpression may not reflect those seen
in primary breast cancers, there is still mechanistic value
in this approach, as utilized in this study to demonstrate
the constancy of the TIMP-2 mediated activation of
proMMP-2 by MT1-MMP. With this work we want to
challenge the long-standing view that MMPs, particu-
larly MT1-MMP, exert their role in cancer progression
as proteases that predominately degrade ECM compo-
nents to allow cancer cell invasion, and instead suggest a
subtle role for MT1-MMP in tumour progression as
metastatic cancer appears to be better represented by
low levels of inhibited MT1-MMP protein.
Conclusions
Our findings that low levels of MT1-MMP are physiolo-
gically relevant suggest that very high levels MT1-MMP
overexpression represents a non-relevant level of MT1-
MMP expression. Excessive ECM degradation mediated
by high levels of MT1-MMP is not permissive to cell mi-
gration and tumourigenesis, while low levels of MT1-
MMP promote extravasation and vascularization in vivo.
Additional files
Additional file 1: Figure S1. MCF-7 breast cancer cells expressing high
levels of MT1-MMP displayed the well-characterized relationship of TIMP-2
mediated proMMP-2 activation. (a) MCF-7 cells were transiently transfected
with TIMP-2 or ALA + TIMP-2 and the protein lysate and media were
collected for analysis using immunoblot (top) and reverse zymography
(bottom) to examine TIMP-2 protein levels. β-actin was used as a loading
control. Reverse zymography analysis shows that TIMP-2 inhibits MMP
activity (dark bands), whereas ALA + TIMP-2 is devoid of this function
(light bands) due to the non-functional N-terminal domain. (b) Reverse
zymography of MCF-7 and MT1-MMP cell lines incubated for 15 min or
12 h with TIMP-2 or ALA + TIMP-2 CM diluted 1:100 to show TIMP-2
levels in the media post-incubation. Serum free media with CM diluted
from mock-transfected cells was used as a control. (c) Immunoblot analysis
of serially diluted recombinant TIMP-2 and TIMP-2 CM. The image of
the bottom blot is a transformed version of the top blot to visualize
the banding pattern for the recombinant TIMP-2 samples. Based on
densitometry analysis (not shown), the concentration of TIMP-2 protein in
TIMP-2 CM is estimated to be approximately 10 μg/ml. (d) MCF-7 and MT1-
MMP cell lines were incubated for 12 h with proMMP-2 CM supplemented
with increasing dilutions of TIMP-2 or ALA + TIMP-2 CM (1:100; 1 part CM,
100 parts SF media) and then this media was assayed using zymography
and reverse zymography to assess proMMP-2 activation and TIMP-2 levels,
respectively. Low levels (1:100) of TIMP-2 enhance activation of proMMP-2
by MCF-7 cells expressing high levels of MT1-MMP (red arrows), whereas
high levels of TIMP-2 (Full CM;undiluted) inhibit this activation process
(blue arrows). (JPG 2995 kb)
Additional file 2: Figure S2. MCF-7 breast cancer cells expressing low
levels of MT1-MMP and exposed to high levels of TIMP-2 showed rapid
activation of the ERK pathway. Representative immunoblot analysis of
ERK1/2 activation after MCF-7 and MT1-MMP expressing cell lines were
seeded and incubated for 12 h (top) or 15 min (bottom) with media
containing 10 % FBS or SF media supplemented with different dilutions of
TIMP-2 or ALA + TIMP-2 CM (CM:SF). Total ERK1/2 was used as a loading
control. Quantification of these immunoblots is shown in Fig. 4a.
(JPG 2168 kb)
Additional file 3: Time-lapse analysis of ECM degradation and cell
migration of MCF-7 MT1-MMP cells. Parental MCF-7 (Additional file 3), and
MT1-MMP C1, C2, and C3 (Additional files 4, 5 and 6, respectively) cells stably
expressing zsGreen (green) were seeded on Alexa594 gelatin coated
coverslips (red) and incubated in a live imaging chamber at 37 °C, 5 % CO2.
Images were acquired using a Leica DM16000 B fluorescent microscope.
Frames were taken every 10 min for 20 h and compiled into time-lapse
movies using ImageJ. Representative stills of each cell line at time 0 and
20 h are shown in Fig. 6. Scale bars = 100 μm. (AVI 11745 kb)
Additional file 4: Time-lapse analysis of ECM degradation and cell
migration of MCF-7 MT1-MMP cells. Parental MCF-7 (Additional file 3), and
MT1-MMP C1, C2, and C3 (Additional files 4, 5 and 6, respectively) cells stably
expressing zsGreen (green) were seeded on Alexa594 gelatin coated
coverslips (red) and incubated in a live imaging chamber at 37 °C, 5 % CO2.
Images were acquired using a Leica DM16000 B fluorescent microscope.
Frames were taken every 10 min for 20 h and compiled into time-lapse
movies using ImageJ. Representative stills of each cell line at time 0 and
20 h are shown in Fig. 6. Scale bars = 100 μm. (AVI 17197 kb)
Additional file 5: Time-lapse analysis of ECM degradation and cell
migration of MCF-7 MT1-MMP cells. Parental MCF-7 (Additional file 3), and
MT1-MMP C1, C2, and C3 (Additional files 4, 5 and 6, respectively) cells stably
expressing zsGreen (green) were seeded on Alexa594 gelatin coated
coverslips (red) and incubated in a live imaging chamber at 37 °C, 5 % CO2.
Images were acquired using a Leica DM16000 B fluorescent microscope.
Frames were taken every 10 min for 20 h and compiled into time-lapse
movies using ImageJ. Representative stills of each cell line at time 0 and
20 h are shown in Fig. 6. Scale bars = 100 μm. (AVI 14891 kb)
Additional file 6: Time-lapse analysis of ECM degradation and cell
migration of MCF-7 MT1-MMP cells. Parental MCF-7 (Additional file 3), and
MT1-MMP C1, C2, and C3 (Additional files 4, 5 and 6, respectively) cells stably
expressing zsGreen (green) were seeded on Alexa594 gelatin coated
coverslips (red) and incubated in a live imaging chamber at 37 °C, 5 % CO2.
Images were acquired using a Leica DM16000 B fluorescent microscope.
Frames were taken every 10 min for 20 h and compiled into time-lapse
movies using ImageJ. Representative stills of each cell line at time 0 and
20 h are shown in Fig. 6. Scale bars = 100 μm. (AVI 18100 kb)
Additional file 7: ADAPT workflow for automated analysis of cell
migration. Shown is an example of the ADAPT plugin and associated
trajectory visualization of the MCF-7 MT1-MMP C2 video (Additional file 5).
Additional file 5 is shown as the overlay of zsGreen cells (green) and
Alexa594 gelatin coating (red), as well as the individual channels (top). The
zsGreen channel was used for the ADAPT analysis (bottom, left) to yield a
trajectory visualization of individual cells from initial point of tracking
(bottom, right). Three videos from independent experiments were analyzed
in this manner and the trajectory visualization from each was used to
quantify individual cell migration after 20 h. Cell migration data is compiled
in Fig. 6b. Scale bars = 100 μm. (MOV 5300 kb)
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Additional file 8: Figure S3. MCF-7 cells expressing high levels of MT1-
MMP released cell fragments in 3D culture, whereas cells expressing low
levels of MT1-MMP displayed a protrusive migratory phenotype. (a) MCF-7
and MT1-MMP cell lines were embedded in 50 % Matrigel and incubated
for 5 days in media containing 10 % FBS. Between days 2 and 5, samples
were placed in a live imaging chamber and imaged at 20× magnification at
the same stage position every 30 min for 72 h to make timelapse movies
showing cell dynamics in 3D culture (Additional files 9, 10, 11 and 12).
Shown are stills at three different time points for each sample showing
colonies that retain circularity (white arrows), release cell fragments (green
arrows) or display protrusions and migratory behavior (red arrows). Scale
bars = 100 μm. (b) MCF-7 and MT1-MMP cell lines stably expressing
zsGreen were embedded in 50 % Matrigel for 5 days and processed
for immunofluorescence to visualize nuclei, zsGreen protein, MT1-
MMP protein and F-actin distribution. Samples were imaged using
confocal microscopy at 20× magnification and displayed as a 3D volume
overlay and the individual channels. Green squares show single cells
surrounding a colony, white squares highlight the insets on the right
showing F-actin disseminations (green arrows) and F-actin protrusions
(red arrows). Quantification of this analysis is shown in Fig. 9c. Scale
bars = 100 μm. (JPG 5795 kb)
Additional file 9: Time-lapse analysis of 3D culture dynamics of MCF-7
MT1-MMP cells. Parental MCF-7 (Additional file 9), and MT1-MMP C1, C2,
and C3 (Additional files 10, 11 and 12, respectively) cells were embedded in
50 % matrigel and incubated in a live imaging chamber at 37 °C, 5 % CO2.
Z-stacks (100 μm, 5 μm slices) were acquired using a Leica DM16000 B
microscope. Frames were taken every 30 min for 72 h and focal planes
showing colony features with the greatest clarity were compiled into time-
lapse movies using ImageJ. Representative stills of each cell line at three
different time points are shown in Additional file 8: Figure S3. Scale
bars = 100 μm. (AVI 14794 kb)
Additional file 10: Time-lapse analysis of 3D culture dynamics of MCF-7
MT1-MMP cells. Parental MCF-7 (Additional file 9), and MT1-MMP C1, C2,
and C3 (Additional files 10, 11 and 12, respectively) cells were embedded in
50 % matrigel and incubated in a live imaging chamber at 37 °C, 5 % CO2.
Z-stacks (100 μm, 5 μm slices) were acquired using a Leica DM16000 B
microscope. Frames were taken every 30 min for 72 h and focal planes
showing colony features with the greatest clarity were compiled into time-
lapse movies using ImageJ. Representative stills of each cell line at three
different time points are shown in Additional file 8: Figure S3. Scale
bars = 100 μm. (AVI 14660 kb)
Additional file 11: Time-lapse analysis of 3D culture dynamics of MCF-7
MT1-MMP cells. Parental MCF-7 (Additional file 9), and MT1-MMP C1, C2,
and C3 (Additional files 10, 11 and 12, respectively) cells were embedded in
50 % matrigel and incubated in a live imaging chamber at 37 °C, 5 % CO2.
Z-stacks (100 μm, 5 μm slices) were acquired using a Leica DM16000 B
microscope. Frames were taken every 30 min for 72 h and focal planes
showing colony features with the greatest clarity were compiled into time-
lapse movies using ImageJ. Representative stills of each cell line at three
different time points are shown in Additional file 8: Figure S3. Scale
bars = 100 μm. (AVI 14676 kb)
Additional file 12: Time-lapse analysis of 3D culture dynamics of MCF-7
MT1-MMP cells. Parental MCF-7 (Additional file 9), and MT1-MMP C1, C2,
and C3 (Additional files 10, 11 and 12, respectively) cells were embedded in
50 % matrigel and incubated in a live imaging chamber at 37 °C, 5 % CO2.
Z-stacks (100 μm, 5 μm slices) were acquired using a Leica DM16000 B
microscope. Frames were taken every 30 min for 72 h and focal planes
showing colony features with the greatest clarity were compiled into time-
lapse movies using ImageJ. Representative stills of each cell line at three
different time points are shown in Additional file 8: Figure S3. Scale
bars = 100 μm. (AVI 15106 kb)
Additional file 13: Figure S4. Excision of vascularized tumours
demonstrated internal blood vessels. A tumour from MDA-MB 231 cells
expressing zsGreen was excised from a chicken embryo 8 days post-
implantation and imaged using brightfield and fluorescence microscopy.
Vessels within the tumour (white arrows) can be seen by the presence of
blood (brightfield) and absence of fluorescent signal (zsGreen), which indi-
cate that these vessels originate from the chicken embryo. Cutting this
tumour in half and rotating the pieces to reveal the inside of the tumour
confirms internal vascularization. Scale bars = 2 mm. (JPG 6034 kb)
Additional file 14: Real-time intravital imaging of extravasated MCF-7
MT1-MMP C3 cells. MCF-7 MT1-MMP C3 cells stably expressing zsGreen
(green) were injected intravenously into the CAM vasculature of day 13
chicken embryos and imaged 24 h post-injection after labeling the vessels
with lectin rhodamine (red). A movie in real-time was acquired using the
resonant scanner of a Nikon A1R+ confocal microscope. The focus of the
microscope was moved manually to show that a single C3 cells has extrava-
sated from the CAM vasculature and shows a protrusion into the stroma
(devoid of lectin-rhodamine signal). Scale bar = 100 μm. (MOV 9808 kb)
Additional file 15: Figure S5. Immunological detection of MT1-MMP
protein can be confounding depending on antibody utilized. (a) Immunoblot
analysis of MCF-7 and MDA-MB 231 MT1-MMP cell lines (top), or MCF-7,
MDA-MB 231 and HS578t breast cancer cell lines (bottom) using a polyclonal
anti-MT1-MMP rabbit antibody (AB6004 – Millipore). (b) Immunoblot analysis
of MCF-7, MDA-MB 231, and HS578t breast cancer cells, along with the MCF-
7 MT1-MMP cell lines, using a monoclonal rabbit antibody (AB51075- Abcam).
These blots were ran for 6 h at 140 V on a 15 % acrylamide gel to ensure
optimal band separation. On the left is a normal exposure of each blot and
on the left is transformed version to clearly demonstrate banding pattern.
Arrows indicate non-specific signal, whereas asterisks indicate specific signal
pertaining to MT1-MMP isoforms (green – pro form, red- active form, orange
– degradation forms). Note the substantial amount of non-specific signal
obtained when using AB6004 compared to AB51074, despite both antibodies
being able to specifically detect multiple isoforms of MT1-MMP. Of particular
interest are the red and green non-specific bands obtained using AB6004,
which could be misinterpreted as pro- and active forms of MT1-MMP,
respectively (see banding pattern for MT1-MMP deficient MCF-7 cells).
(JPG 3520 kb)
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